CN1278791A - 制造氮杂环烷基烷酰基假四肽的方法 - Google Patents

制造氮杂环烷基烷酰基假四肽的方法 Download PDF

Info

Publication number
CN1278791A
CN1278791A CN98810983A CN98810983A CN1278791A CN 1278791 A CN1278791 A CN 1278791A CN 98810983 A CN98810983 A CN 98810983A CN 98810983 A CN98810983 A CN 98810983A CN 1278791 A CN1278791 A CN 1278791A
Authority
CN
China
Prior art keywords
alkyl
protecting group
acid
cycloalkyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98810983A
Other languages
English (en)
Chinese (zh)
Inventor
J·J·门瑟尔
R·斯塔姆勒
C·多比
M·拉威尼
B·J·瓦纳斯
刘·罗伯特·承桓
P·莱昂
G·A·德尼托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN1278791A publication Critical patent/CN1278791A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
CN98810983A 1997-10-10 1998-10-09 制造氮杂环烷基烷酰基假四肽的方法 Pending CN1278791A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6171997P 1997-10-10 1997-10-10
US60/061,719 1997-10-10

Publications (1)

Publication Number Publication Date
CN1278791A true CN1278791A (zh) 2001-01-03

Family

ID=22037674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98810983A Pending CN1278791A (zh) 1997-10-10 1998-10-09 制造氮杂环烷基烷酰基假四肽的方法

Country Status (18)

Country Link
US (1) US6180759B1 (cg-RX-API-DMAC7.html)
EP (1) EP1030831A4 (cg-RX-API-DMAC7.html)
JP (1) JP2001519411A (cg-RX-API-DMAC7.html)
KR (1) KR20010024467A (cg-RX-API-DMAC7.html)
CN (1) CN1278791A (cg-RX-API-DMAC7.html)
AP (1) AP1057A (cg-RX-API-DMAC7.html)
AU (1) AU738114B2 (cg-RX-API-DMAC7.html)
BG (1) BG104408A (cg-RX-API-DMAC7.html)
BR (1) BR9814068A (cg-RX-API-DMAC7.html)
CA (1) CA2306823A1 (cg-RX-API-DMAC7.html)
EA (1) EA002724B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0003788A3 (cg-RX-API-DMAC7.html)
IL (1) IL135553A0 (cg-RX-API-DMAC7.html)
NO (1) NO20001793D0 (cg-RX-API-DMAC7.html)
OA (1) OA11369A (cg-RX-API-DMAC7.html)
PL (1) PL340915A1 (cg-RX-API-DMAC7.html)
SK (1) SK4332000A3 (cg-RX-API-DMAC7.html)
ZA (1) ZA989241B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100422147C (zh) * 2002-11-01 2008-10-01 北京天衡药物研究院 一种制备0-取代磺酰酪氨酸类化合物的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331772A1 (en) * 1996-08-21 1999-08-02 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of n-[n-n-(4-piperidin-4-yl)-n-ethylglycin] compounds
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
CN103254265B (zh) * 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042487A (en) * 1964-06-25 1966-09-14 Ici Ltd Polypeptide derivatives
JPS6322081A (ja) * 1986-07-11 1988-01-29 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE914334A1 (en) * 1990-12-17 1992-06-17 Black James Foundation Tetrapeptide derivatives and analogues
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
UA44258C2 (uk) * 1993-10-15 2002-02-15 Рон-Пуленк Рорер Фармасьютікалз Інк. Антитромботичні азациклоалкілалканоілпептиди та псевдопептиди, фармацевтична композиція, що їх містить, спосіб профілактики або лікування тромбозу у ссавців (варіанти)
GB9516994D0 (en) * 1995-08-18 1995-10-18 Iaf Biochem Int Solution synthesis of peripheral acting analgestic opioid tetrapeptides
EP0768384B1 (en) * 1995-10-11 2001-06-13 Holland Sweetener Company V.o.F. Improved enzymatic coupling reaction of N-protected-L-aspartic acid and phenylalanine methyl ester
PL331772A1 (en) * 1996-08-21 1999-08-02 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of n-[n-n-(4-piperidin-4-yl)-n-ethylglycin] compounds
NL1005808C2 (nl) * 1997-04-14 1998-10-19 Dsm Nv Hexahydro-aspartaamamiden en werkwijze voor de bereiding ervan.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100422147C (zh) * 2002-11-01 2008-10-01 北京天衡药物研究院 一种制备0-取代磺酰酪氨酸类化合物的方法

Also Published As

Publication number Publication date
KR20010024467A (ko) 2001-03-26
BR9814068A (pt) 2000-09-26
EP1030831A1 (en) 2000-08-30
SK4332000A3 (en) 2000-12-11
EA200000399A1 (ru) 2000-10-30
AP2000001781A0 (en) 2000-06-30
OA11369A (en) 2004-01-27
US6180759B1 (en) 2001-01-30
AU738114B2 (en) 2001-09-06
BG104408A (bg) 2000-12-29
EP1030831A4 (en) 2003-01-02
IL135553A0 (en) 2001-05-20
HUP0003788A2 (hu) 2001-04-28
ZA989241B (en) 1999-06-04
NO20001793L (no) 2000-04-06
AU1074699A (en) 1999-05-03
CA2306823A1 (en) 1999-04-22
AP1057A (en) 2002-04-08
JP2001519411A (ja) 2001-10-23
PL340915A1 (en) 2001-03-12
HUP0003788A3 (en) 2001-05-28
EA002724B1 (ru) 2002-08-29
NO20001793D0 (no) 2000-04-06

Similar Documents

Publication Publication Date Title
CN1036399C (zh) 三肽抗凝血酶剂的制备方法
CN1127511C (zh) 白介素－1β转化酶的抑制剂
US7816377B2 (en) Tubulysin analogues
CA2117121A1 (en) Peptides
CN1149876A (zh) 弹性蛋白酶的全氟烷基酮抑制剂及其制备方法
CN1372566A (zh) 抗细小核糖核酸病毒的化合物和组合物,它们的药物用途,及其合成原料
CN1231659A (zh) N[n－n－(4－哌啶－4－基)丁酰基)－n－乙基甘氨酰基]化合物的不吸湿的稳定结晶形式
CN1132511A (zh) 基质金属蛋白酶抑制剂
CN1304415C (zh) 作为ace和nep抑制剂的吡喃衍生物
CN1255498A (zh) 生长激素促分泌剂的制备方法和中间体
CN1231671A (zh) 抗血栓形成的氮杂环烷基链烷酰基肽和假肽
CN1604908A (zh) 制备棘白菌素衍生物的方法
CN1278791A (zh) 制造氮杂环烷基烷酰基假四肽的方法
CN1137891C (zh) 生长激素促分泌素的制备方法
HK1033935A (en) Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
CN1041366A (zh) 具有t细胞抑制基因活性的肽的合成方法
CN1234804A (zh) N－(1(s)－乙氧羰基－3－苯丙基)－l－丙氨酰基－氨基酸药理上可接受的盐的制备方法
CN1617881A (zh) 化学方法
CN1039017A (zh) 新化合物的制备方法
CN1203602A (zh) α－酮酯和α－酮酰胺的酰化烯醇衍生物
CN87105898A (zh) N-(s-3-烷基庚酰基)-D-r-谷氨酰基-甘氨酰基-D-丙氨酰的制备方法和中间体
MXPA00003470A (es) Procedimientos para preparar azacicloalquilalcanoil pseudotetrapeptidos
JP2005325061A (ja) シクロスポリン類の製造方法
JPS63183551A (ja) ノルスタチンおよびノルシクロスタチンポリペプチド
WO1999019294A1 (en) Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1033935

Country of ref document: HK